Monday, January 2, 2023

< + > With FDA Accelerated Approval Of Alzheimer’s Drug Lecanemab Likely January 6th, Discussion Turns To Price And Reimbursement

Lecanemab’s PDUFA date for its potential accelerated approval is January 6th. The product could launch after its FDA approval. Now the discussion turns to what price it will be launched at, and whether it will eventually be reimbursed by CMS, the predominant payer for a product such as lecanemab.

No comments:

Post a Comment

< + > Bonus Features – November 15, 2026 – 69% or healthcare pros want their orgs to use more AI, 38% of patients are comfortable using AI to schedule appointments, plus 36 more stories

Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...